Traders should monitor for potential downward pressure on VERA shares, especially given the breadth and coordination of the sell-off. Consider whether this reflects profit-taking post-runup or a lack of confidence ahead of an upcoming catalyst. Watch for any follow-up filings or news.
VERA drugs
VERA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $42.06entry
- T+1 · 9mo ago +0.74%α +0.00% · $42.37
- T+5 · 9mo ago −3.90%α −4.52% · $40.42
- T+20 · 8mo ago −3.16%α +0.78% · $40.73
- T+60 · 6mo ago −18.33%α −26.58% · $34.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Vera Therapeutics, including the CEO and CFO, collectively sold over $1.4 million in shares on February 23, 2026, all through open-market transactions at the same price. This represents a coordinated insider selling event involving nearly the entire C-suite.
Key Financial Metrics
Key Facts
- CEO Marshall Fordyce sold 16,925 shares for $710,577.51, the largest individual transaction.
- All seven insiders executed open-market sales (Form 4 code 'S') on the same day at $41.9839 per share.
- Total value of the cluster: $1,406,042.71 across 33,490 shares sold.
- Selling executives include all key C-suite officers: CEO, CFO, CMO, COO, CCO, CRO, and SVP Finance.
- No purchases or non-cash transactions (e.g., grants, exercises) were part of this cluster.
Financial Impact
$1.41 million in insider selling over one day
Risk Factors
- Perception of insider pessimism given the complete absence of buying and participation by top leadership.
- Potential for negative market reaction due to concentration of selling among decision-makers with material non-public information.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-VERA-1772067667098 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers